Home > Healthcare > Pharmaceuticals > Finished Drug Form > Dyspepsia Drugs Market
Dyspepsia Drugs Market Size
- Report ID: GMI7670
- Published Date: Dec 2023
- Report Format: PDF
Dyspepsia Drugs Market Size
Dyspepsia Drugs Market size accounted for USD 9.7 billion in 2023 and is set to register 4.5% CAGR between 2024 and 2032. The robust growth of this market is majorly attributed to factors such as increasing prevalence of dyspepsia, growing aging population, and rising preference for over the counter (OTC) drugs/medications.
For instance, according to the Journal of Neurogastroenterology and Motility (JNM), the prevalence of functional dyspepsia is estimated to be around 10-40% in western countries, and about 5-30% in Asia. Thus, as the prevalence of dyspepsia continues to increase, there is a growing pool of individuals seeking dyspepsia drugs for alleviating the symptom associated with it, thereby augmenting the market expansion. Additionally, the increasing use of proton pump inhibitors (PPIs), and growing research & development activities for development of novel product is expected to support the growth.
Dyspepsia drugs encompass a range of medications designed to alleviate symptoms associated with dyspepsia, a condition characterized by discomfort or pain in the upper abdomen often related to digestion. Dyspepsia, also known as indigestion, typically includes symptoms such as bloating, discomfort, and pain in the upper abdomen.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Dyspepsia Drugs Market Size in 2023: | USD 9.7 Billion |
| Forecast Period: | 2024 to 2032 |
| Forecast Period 2024 to 2032 CAGR: | 4.5% |
| 2032 Value Projection: | USD 14.3 Billion |
| Historical Data for: | 2018 to 2023 |
| No. of Pages: | 180 |
| Tables, Charts & Figures: | 316 |
| Segments covered: | Indication, Drug Type, Medication, Mode, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Dyspepsia Drugs Market Scope
